CSV October 31, 2022 through October 31, 2024 All Errata for USP–NF How to use

×

How to Use

- **Searching:** Type keyword in search field at top of page. Search by all or part of a monograph title. For searches using multiple criteria, you will find items that match each of the specified criteria unless quotation marks are used.
    - For example, a search on Aminosalicylic Acid Tablets will result in anything that contains “Aminosalicyclic” OR “Acid” OR “Tablets”
    - A search for “Aminosalicylic Acid Tablets” will result in anything that specifically contains “Aminosalicylic Acid Tablets”
- **Sorting:** Click on any column header title to sort alphabetically or chronologically in ascending or descending order. Note: the page load column is sorted alphabetically so that a number is ordered by first digit vs. by the actual number; thus, numbers will not always be in order.
    - For example, page 2178 will come before page 74 on a page sort.
- **Downloading:** You can download the Errata table in Comma-separated Value (.csv). The download will include the Errata that you have filtered on.
- **Importing:**You will need to import the file into Excel or Open Office with UTF-8 encoding, as opposed to simply opening it. To import, open Excel or Open Office and select import from the File drop-down. Depending on the version you are using, you should be presented with import formatting options to include UTF-8 as one of the first steps. Importing via UTF-8 should eliminate odd character conversions.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
LORAZEPAM	ADDITIONAL R	*USP39–NF34*	4620	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	Line 3 of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
INJECTION	EQUIREMENTS/*USP Reference Standards <11>*							Lorazepam Related Compound B RS: Change $C_{13}H_9ClNO$ to: $C_{13}H_9Cl_2NO$
NALTREXONE HYDROCHLORIDE	*Related compounds*	*USP39–NF34*	4985	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	Line 5: Change $10F(C/W)(r_U / r_S)$ to: $1000F(C/W)(r_U/r_S)$
RANITIDINE INJECTION	*USP Reference standards <11>*	*USP39–NF34*	5670	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	Line 2 of USP Ranitidine Related Compound C RS: Change *N*-[2-[[[5-[(Dimethylamino)methyl]-2-furanyl]methyl]sulfinyl]ethyl]-*N*-methyl-2-nitro-1,1-ethenediamine. to: *N*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								-{2-[({5-[(Dimethylamino)methyl]-2-furanyl}meth
								N ?-methyl-2-nitro-1,1-ethenediamine.
TETRACYCLINE HYDROCHLORIDE CAPSULES	ASSAY/ *Procedure*	*USP39–NF34*	6082	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	Line 6 of *Sample solution*: Change dilute with *Diluent* to volume. to: dilute with *Solution A* to volume.
VINPOCETINE	IMPURITIES/*Organic Impurities*	*USP39–NF34*	6880	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	Footnote a of *Table 1*: Change Ethyl (12*RS*,13a*SR*,13b*SR*)-13a-ethyl-12-hydroxy-2,3,5,6,12,13,13a,13b-octa

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								hydro-1*H*-indolo[3,2,1-*de*]pyrido[3,2,1-*ij*][1,5]naphthyridine-12-carboxylate (ethyl vincaminate). to: Ethyl (12*S*,13a*S*,13b*S*)-13a-ethyl-12-hydroxy-2,3,5,6,12,13,13a,1
								H-indolo[3,2,1-*de*]pyrido[3,2,1-*ij*][1,5]naphthyridine-12-carboxylate (ethyl vincaminate).

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								AND Footnoteb of *Table 1*: Change Methyl (13a*S*,13b*S*)-13a-ethyl-9-methoxy-2,3,5,6,13a,13b-hexahydro-1*H*-indolo[3,2,1-*de*]pyrido[3,2,1-ij][1,5]naphthyridine-12-carboxylate (apovincamine). to: Methyl (13a*S*,13b*S*)-13a-ethyl-2,3,5,6,13a,13b-hexahydro-1*H*-indolo[3,2,1-*de*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								]py rido[3 ,2,1-*ij*][1,5]naphthyridi ne-12-carboxyla te (apovincamine). AND Footnote d of *Table 1*: Change Ethyl (12*RS*,13a *RS*,13b*RS*)-13a -ethyl-2,3,5,6,12 ,13,13a,13b- octa hydro-1*H* -in dolo[3,2,1-*de*]py rido[3 ,2,1-*ij*][1,5]naphthyridi ne-12-carboxyla te (dihydrovinpo cetine). to: Ethyl (12*R*,13a*S*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								,13b*S*)-13a-ethyl-2,3,5,6,12,13,13a,13b-octa hydro-1*H*-indolo[3,2,1-*de*]pyrido[3,2,1-*ij*][1,5]naphthyridine-12-carboxylate (dihydrovinpocetine).
REAGENTS, INDICATORS AND SOLUTIONS	REAGENTS/*6. General Tests for Reagents*/*6.2 Amino Nitrogen Test in Reagents*	*USP39–NF34*	2080	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	In the numerator of the equation: Change 2.8 to: 14 AND Add × *f* AND Line 10: Change where %LOD is the percentage of loss on

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								drying. to: where *f* is the correction factor obtained in the standardization of 0.2 N sodium hydroxide and %LOD is the percentage of loss on drying.
HAZARDOUS DRUGS—HANDLING IN HEALTHCARE SETTINGS	5. FACILITIES AND ENGINEERING CONTROLS/*5.3 Compounding*	*First Supplement to USP39–NF34*	7721	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	First bullet in second paragraph: Change • Be externally vented through high-efficiency particulate air (HEPA) filtration to: • Be externally vented
IMIQUIMOD CREAM	IM PURITIES/*Organic Impurities*	*USP39–NF34*	4289	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	Row 2 of Column 3 of *Table 2*: Change 1.5 to: 1.15 AND

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Row 3 of Column 3 of *Table 2*: Change 1.15 to: 1.5
METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS	PERFORMANCE TESTS/ *Dissolution <711>*	*USP39–NF34*	4766	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	Line 3 of *Test 3*: Change *Medium, Apparatus 1, Apparatus 2*, and *Analysis*: to: *Medium, Apparatus 1*, and *Apparatus 2*:
PALIPERIDONE	CHEMICAL INFORMATION	*USP39–NF34*	5253	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	Line 5: Change (9*RS*)-3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidin-1-yl]]ethyl]-9-hydroxy-2-methyl-6,7,8,9-tetrahydro-4*H*-pyrido[1,2-*a*]pyrimidin-4-one to: (9*RS*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
RANITIDINE IN SODIUM CHLORIDE INJECTION	*USP Reference standards <11>*	*USP39–NF34*	5673	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	)-3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidin-1-yl]]ethyl]-9-hydroxy-2-methyl-6,7,8,9-tetrahydro-4*H*-pyrido[1,2-*a*]pyrimidin-4-one Line 2 of USP Ranitidine Related Compound C RS: Change *N*-[2-[[[5-[(Dimethylamino)methyl]-2-furanyl]methyl]sulfinyl]ethyl]-*N*-methyl-2-nitro-1,1-ethenediamine. to: *N*-{2-[({5-[(Dimethylamino)methyl]-2-furanyl}meth

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								N ?-methyl-2-nitro -1,1-ethenedia mine.
CHONDROITIN SULFATE SODIUM, SHARK	SPECIFIC TESTS/*Clarity and Color of Solution*	*USP39–NF34*	6570	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	Line 2 of *Instrumental conditions*: Change (See *Spectrophotometry and Light-Scattering <851>*.) to: (See *Ultraviolet-Visible Spectroscopy <857>*.)
OLEYL ALCOHOL	ASSAY/ *Procedure*	*USP39–NF34*	7424	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	Line 1 of *Standard solution*: Change Prepare 1.0 mg/mL of USP Oleyl Alcohol RS in *Internal standard solution*, and

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								heat the solution in a sealed container in a 50° water bath until oleyl alcohol is dissolved. Allow the solution to cool to room temperature, and mix well. to: 1.0 mg/mL of USP Oleyl Alcohol RS in *Internal standard solution* AND Line 1 of *Sample solution*: Change Prepare 1.0 mg/mL of Oleyl Alcohol in *Internal standard solution*, and heat the

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								solution in a sealed container in a 50° water bath until oleyl alcohol is dissolved. Allow the solution to cool to room temperature, and mix well. to: 1.0 mg/mL of Oleyl Alcohol in *Internal standard solution*
DIAZEPAM INJECTION	*Assay*	*USP39–NF34*	3445	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	Line 7 of *Procedure*: 50C / $V(R_U / R_S)$ to: $50(C / V)(R_U / R_S)$
LORAZEPAM ORAL CONCENTRATE	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP39–NF34*	4621	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	Line 3 of Lorazepam Related Compound B RS: Change $C_{13}H_9ClNO$ to: C

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								$^{13}H_9Cl_2NO$

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
NICOTINE POLACRILEX	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP39–NF34*	5061	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	Add USP Polacrilex Resin RS
RANITIDINE ORAL SOLUTION	*USP Reference standards <11>*	*USP39–NF34*	5671	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	Line 2 of USP Ranitidine Related Compound C RS: Change *N* -[2-[[[5-[(Dimethylamino)methyl]-2-furanyl]methyl] sulfinyl]ethyl]-*N* -methyl-2-nitro-1,1-ethenediamine. to: *N* -{2-[({5-[(Dimethylamino)methyl]-2-furanyl}meth *N* ?-methyl-2-nitro

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								-1,1-ethenediamine.
TROSPIUM CHLORIDE	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP39–NF34*	6287	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	Line 3 of USP Trospium Chloride Related Compound C RS:Change (1*R*,3*r*,5*S*)-3-Hydroxyspiro[8-azoniabicyclo[3.2.1]octane-8,1?-pyrrolidinium] chloride. to: (1*R*,3*r*,5*S*)-3-Hydroxyspiro[8-azoniabicyclo[3.2.1]octane-8,1?-pyrrolidinium] chloride, or (1*R*,3*r*,5*S*)-3-Hydroxyspiro[bicyclo[3.2.1]octane-8,1?-pyrrolidin]-1?-ium chloride.
CETYL ALCOHOL	IMPURITIES/*Limit of Related Fatty Alcohols*	*USP39–NF34*	7239	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	Line 1 of *Sample solution*: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								1 mg/mL of Cetyl Alcohol in ethanol to: Prepare 1.0 mg/mL of Cetyl Alcohol in ethanol, and heat the solution in a sealed container in a 50° water bath until cetyl alcohol is dissolved. Allow the solution to cool to room temperature, and mix well.
ALPRAZOLAM EXTENDED-RELEASE TABLETS	PERFORMANCE TESTS/ *Dissolution <711>*	*USP39–NF34*	2389	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	Variable definition list of second equation in *Test 2*/*Analysis*: Change V_S = volume of the *Sample solution* withdrawn at each time point

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								and replaced with *Medium* (mL) to: V_S = volume of the *Sample solution* withdrawn at each time point (mL) AND Variable definition list of second equation in *Test 3/Analysis*: Change V_S = volume of the *Sample solution* withdrawn at each time point and replaced with *Medium* (mL) to: V_S = volume of the *Sample solution* withdrawn at each time point

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								(mL)
PAROXETINE EXTENDED-RELEASE TABLETS	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*First Supplement to USP39–NF34*	8121	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	USP Paroxetine Related Compound B RS: Add $C_{19}H_{21}NO_3 \cdot HCl$ 347.84
LORAZEPAM	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP39–NF34*	4618	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	Line 3 of USP Lorazepam Related Compound B RS: Change $C_{13}H_9ClNO$ to: $C_{13}H_9Cl_2NO$
MYCOPHENOLATE SODIUM	ASSAY/*Procedure*	*USP39–NF34*	4965	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	Line 3: Change *Solvent A* to: *Solution A* AND Line 5: Change *Solvent B* to: *Solution B*
PALIPERIDONE	IMPURITIES/*Organic Impurities*/*System suitabil*	*USP39–NF34*	5253	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	Line 3 of *Resolution*: Change hydroxybenzyl to: hydroxybenzoyl

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	ity/Suitability requirements							
SAMARIUM Sm 153 LEXIDRONAM INJECTION	*Other requirements*	*USP39–NF34*	5791	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	Line 1: Change *Injections and Implanted Drug Products <1>*; not subject to *Container Content*. to: Meets the requirements of *Injections and Implanted Drug Products <1>*; not subject to *Container content*.
CHONDROITIN SULFATE SODIUM, SHARK	COMPOSITION /*Disaccharide Composition*	*USP39–NF34*	6570	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	Line 2 of *Chondroitinase ABC solution*: Change 10.0 mL of *Buffer solution* to: 1.0 mL of *Buffer solution* AND Line 4 of *Analysis*: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								and 1.0 mL to: and 0.1 mL
SEMISOLID DRUG PRODUCTS—PERFORMANCE TESTS	IN VITRO PERFORMANCE TESTS	*USP39–NF34*	1869	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	Line 7 of *Application of Drug Release*: Change The individual amounts of drug released from *R* is plotted versus time, to: The individual amounts of drug released from *R* are plotted versus the square root of time,
SODIUM CETOSTEARYL SULFATE	IMPURITIES/*Limit of Sodium Chloride and Sodium Sulfate*/*Sodium sulfate*/ *Titrimetric system*	*USP39–NF34*	7518	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	Line 1 of *Endpoint detection*: Change Potentiometric to: Visual
DICLOFENAC SODIUM EXTE	IM PUR	*USP39–NF34*	3460	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	Line 1 of *Standard*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
NDED-RELEASE TABLETS	ITIES/*Organic Impurities*							*solution*: Change 0.001 mg/mL of USP Diclofenac Sodium RS in *Diluent* to: 0.001 mg/mL each of USP Diclofenac Sodium RS and USP Diclofenac Related Compound A RS in *Diluent*
LORAZEPAM TABLETS	ADDITIONAL REQUIREMENTS/*USP Reference Standards RS <11>*	*USP39–NF34*	4622	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	Line 3 of USP Lorazepam Related Compound B RS: Change $C_{13}H_9ClNO$ to: $C_{13}H_9Cl_2NO$
OXANDROLONE TABLETS	*Dissolution <711>/Test 3*	*USP39–NF34*	5193	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	Line 3 of *Chromatographic system*: Change 30-cm column to: 3-cm column
RANITIDINE	*USP Reference*	*USP39–NF34*	5672	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	Line 2 of USP

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
TABLETS	*standards <11>*							Ranitidine Related Compound C RS: Change *N* -[2-[[[5-[(Dimethylamino)methyl]-2-furanyl]methyl] su lfinyl]ethyl]-*N* -methyl-2-nitro-1,1-ethenediamine. to: *N* -{2-[({5-[(Dimethylamino)methyl]-2-furanyl}meth *N* ?-methyl-2-nitro-1,1-ethenediamine.
CHONDROITIN SULFATE SODIUM, SHARK	IM PURITIES/*Limit of Protein*	*USP39–NF34*	6570	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	Line 2 of *Instrumental conditions*: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								(See *Spectrophotometry and Light-Scattering <851>*.) to: (See *Ultraviolet-Visible Spectroscopy <857>*.)
MYRISTYL ALCOHOL	ASSAY/ *Procedure*	*USP39–NF34*	7413	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	Line 1 of *Standard solution*: Change Prepare 1.0 mg/mL of USP Myristyl Alcohol RS in *Internal standard solution*, and heat the solution in a sealed container in a 50° water bath until myristyl alcohol is dissolved. Allow the solution to cool to room temperature,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								and mix well. to: 1.0 mg/mL of USP Myristyl Alcohol RS in *Internal standard solution* AND Line 1 of *Sample solution*: Change Prepare 1.0 mg/mL of Myristyl Alcohol in *Internal standard solution*, and heat the solution in a sealed container in a 50° water bath until myristyl alcohol is dissolved. Allow the solution to cool to room temperature, and mix well.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								to: 1.0 mg/mL of Myristyl Alcohol in *Internal standard solution*
SELENOMETHIONINE	CHEMICAL INFORMATION	*USP38–NF33*	6226	25-Mar-2016	1-Apr-2016	*USP40–NF35*	*USP40–NF35*	Line 3: Change [1464-42-2] to: [3211-76-5]
PLASTIC MATERIALS OF CONSTRUCTION	TEST METHODS/ *Extractions*/*Table 3*	*USP39–NF34*	493	25-Mar-2016	1-Apr-2016	*USP40–NF35*	*USP40–NF35*	Line 1 of footnote b: Change For nonplasticized polyethylene only. to: For polyethylene only.
FLUTICASONE PROPIONATE AND SALMETEROL INHALATION POWDER	ASSAY/ *Procedure*	*USP39–NF34*	4020	25-Mar-2016	1-Apr-2016	*USP40–NF35*	*USP40–NF35*	Line 3 of *System suitability*: Change for salmeterol and fluticasone propionate are to: for fluticasone propionate and

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								salmeterol are
CONTAINERS--PERFORMANCE TESTING	MOISTURE VAPOR TRANSMISSION/*Packaging System Classification for Multiple-Unit Containers and Unit-Dose Containers for Liquid Oral Dosage Forms/ Procedure*	*USP38–NF33*	465	25-Mar-2016	1-Apr-2016	*USP40–NF35*	*USP40–NF35*	Line 1 of the Equation: Change $[(W_{1i} ? W_T) ? (W_{14i} ? W_T) ? (W_{C1} ? W_{C14})] \times 365 \times \{[100/(W_{1i} ? W_T)] \times 14\}$ to: $[(W_{1i} ? W_T) ? (W_{14i} ? W_T) ? (W_{C1} ? W_{C14})] \times 365 \times 100/(W_{1i} ? W_T) \times 14$
PLASTIC MATERIALS OF CONSTRUCTION	SPECIFICATIONS/ *Polyethylene Terephthalate and Polyethylene Terephthalate G/Extractable Metals*	*USP39–NF34*	493	25-Mar-2016	1-Apr-2016	*USP40–NF35*	*USP40–NF35*	Line 1 of *Titanium*: Change 0.1 µg/g. to: 1 µg/g.
CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE TABLETS	IMPURITIES/*Organic Impurities*	*USP39–NF34*	2895	25-Mar-2016	1-Apr-2016	*USP40–NF35*	*USP40–NF35*	Row 3 of Column 1 of *Table 6*:Change Candesartan related compound A[b,c] to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
MEMANTINE HYDROCHLORIDE TABLETS	IMPURITIES/*Organic Impurities*	*Revision Bulletin (Official October 01, 2015)*	Online	25-Mar-2016	1-Apr-2016	*USP40–NF35*	*USP40–NF35*	Candesartan cilexetil related compound A[b,c] Line 3 of *Analysis*: Change of USP Memantine Related Compound E RS or to: of memantine related compound E or AND In the variable definition list: Change r_U = peak response of USP Memantine Related Compound E RS or any individual degradation product from the *Sample solution*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								to: r_U = peak response of memantine related compound E or any individual degradation product from the *Sample solution* *Product* column: Change 10.00 (neat), 5.00, 2.50, 1.25, 0.63, 0.31, 0.16 to: 10.00 (neat), 5.00, 2.50, 1.25, 0.625, 0.3125, 0.15625 AND *Sample 1/HCP ratio* column: Change 4.9, 5.7, 4.8, 5.9, 5.0, 5.1, <6 to: 4.90, 5.70, 4.80, 5.92, 4.96, 5.12, <6
RESIDUAL HOST CELL PROTEIN MEASUREMENT IN BIOPHARMACEUTICALS	4. HCP IMMUNOASSAY METHOD VALIDATION/*4.3 Sample Linearity*/*Table 4*	*Second Supplement to USP38–NF33*	7647	25-Mar-2016	1-Apr-2016	*USP40–NF35*	*USP40–NF35*	

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								AND *Sample 2/HCP ratio* column: Change 2.0, 3.3, 4.0, 5.9, 5.3, 6.1, <6 to: 2.00, 3.30, 4.00, 5.92, 5.28, 6.08, <6 AND *Sample 3/HCP ratio* column: Change 0.3, 0.5, 0.6, 0.9, 1.4, <6, <6 to: 0.32, 0.50, 0.60, 0.88, 1.44, <6, <6 AND *Sample 3/% max ratio value* column: Change 83% to: 61%
PLASTIC MATERIALS OF CONSTRU	TEST METHOD	*USP39–NF34*	493	25-Mar-2016	1-Apr-2016	*USP40–NF35*	*USP40–NF35*	Line 3 of *Plasticized polyvinyl*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
CTION	S/ *Physicochemical Tests/ Absorbance*							*chloride*: Delete Additionally, for nonplasticized polyvinyl chloride materials only, determine the spectrum between 250 and 330 nm in the alcohol sample associated with *Solution S6*.
METHACRYLIC ACID AND ETHYL ACRYLATE COPOLYMER	IM PURITIES/*Limit of Methacrylic Acid and Ethyl Acrylate*	*First Supplement to USP39–NF34*	Online	25-Mar-2016	1-Apr-2016	*USP40–NF35*	*USP40–NF35*	Line 5 of *Standard solution*: Change Mix 10.0 mL of this solution to: Mix 5.0 mL of this solution AND Line 7 of *Standard solution*: Change about 0.67 µg/mL to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								about 0.5 µg/mL Line 4 of *Sample solution*: Change 10.0 mL of this solution to: 5.0 mL of this solution AND In the variable definition list in *Analysis*: Change V_F = final volume of the *Sample solution*, 15 mL *D* = dilution factor for preparation of the *Sample solution*, 5 to: V_F = final volume of the *Sample solution*, 10 mL *D* = dilution factor for

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								preparation of the *Sample solution*, 10
ARGININE HYDROCHLORIDE	SPECIFIC TESTS/*Chloride Content*	*USP38–NF33*	2279	25-Mar-2016	1-Apr-2016	*USP40–NF35*	*USP40–NF35*	Delete the subsection *Blank*: 140 mL of water and 1 mL of dichlorofluorescein TS AND The equation in the *Analysis*: Change Result = [(*V* ? *B*) × *N* × *F* × 100]/*W* to: Result = (*V* × *N* × *F* × 100)/*W* AND Line 10 of *Analysis*: Delete *B* = *Blank* titrant volume (mL)
PLASTIC MATERIALS OF CONSTRUCTION	TEST METHODS/*Extractions*/*Table 3*	*USP39–NF34*	493	25-Mar-2016	1-Apr-2016	*USP40–NF35*	*USP40–NF35*	Column 4 of *S3* row: Change Extractable metals: Al, Sb, As, Ba, Cd, Co, Ge, Hg, Mn, Ni, Pb, Ti, V, and

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Zn to: Extractable metals: Al, As, Ba, Cd, Co, Hg, Mn, Ni, Pb, Ti, V, and Zn
DIPHENHYDRAMINE HYDROCHLORIDE INJECTION	ASSAY/ *Procedure*	*USP39–NF34*	3529	25-Mar-2016	1-Apr-2016	*USP40–NF35*	*USP40–NF35*	Line 1 of *System suitability solution*:Change USP Diphenhydramine Hydrochloride Related Compound A RS to: USP Diphenhydramine Related Compound A RS AND Line 4 of *System suitability*: Change for diphenhydramine hydrochloride related

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								compound A and diphenhydramine hydrochloride are to: for diphenhydramine related compound A and diphenhydramine are
PLASTIC MATERIALS OF CONSTRUCTION	SPECIFICATIONS/ *Polyethylene/Extractable Metals*	*USP39–NF34*	493	25-Mar-2016	1-Apr-2016	*USP40–NF35*	*USP40–NF35*	Line 1 of *Zirconium*: Change 1 µg/g. to: 0.1 µg/g.
DISSOLUTION	INTERPRETATION/*Immediate-Release Dosage Forms/ Immediate-Release Dosage Forms Pooled Sample*	*USP39–NF34*	540	25-Mar-2016	1-Apr-2016	*USP40–NF35*	*USP40–NF35*	Row 3 of Column 1 of *Acceptance Table for a Pooled Sample*: Change S_1 to: S_2 AND Row 4 of Column 1 of *Acceptance Table for a*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Pooled Sample: Change S_1 to: S_3
DIGOXIN	IM PURITIES/*Related Glycosides*/*System suitability*	*Interim Revision Announcement (Official November 01, 2015)*	Online	25-Mar-2016	1-Apr-2016	*USP40–NF35*	*USP40–NF35*	Line 2: Change *Sample: System suitability solution* to: *Samples: System suitability solution* and *Standard solution* AND Line 2 of *Suitability requirements*: Change *Resolution:* NLT 1.5 between the digoxin and lanatoside C peaks *Relative standard deviation:* NMT 2.0%,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								determined from the digoxin peak in replicated injections to: *Resolution:* NLT 1.5 between the digoxin and lanatoside C peaks, *System suitability solution* *Relative standard deviation:* NMT 2.0%, determined from the digoxin peak in replicated injections, *Standard solution*

Pagination

- First page « First
- Previous page ‹ Previous
- …
- Page 22

- Page 23
- Page 24
- Page 25
- Page 26
- Page 27
- Page 28
- Page 29
- Page 30
- …
- Next page Next ›
- Last page Last »